InforSense® Appoints David Hadfield as Chief Operating Officer
News Oct 03, 2006
InforSense Ltd. has announced that David Hadfield, former Spotfire Senior Vice President and General Manager, has joined the Company as Chief Operating Officer.
David will be responsible for the global operations of the Company and will also join InforSense’s Board of Directors.
"David brings demonstrated success in building quality, global organizations," said Prof. Yike Guo, InforSense’s Founder and Chief Executive Officer.
"His sales and marketing experience coupled with excellent general management skills will contribute tremendously as we continue our high rate of growth and new customer acquisition."
"We are extremely pleased that David has joined our management team and we look forward to his many contributions at InforSense."
"This is an exciting time to be a part of InforSense. I was attracted to Inforsense because the company offers a unique approach to deploying real-time analytic applications across the enterprise," said David Hadfield.
"Speaking with customers in a number of industries, they are clearly passionate about the impact that deploying InforSense has on their business."
"We welcome David to our Board of Directors and recognize the depth of commercial and strategic management experience he brings," said Frank Jones, Chairman of InforSense’s Board of Directors.
"His expertise will be invaluable to InforSense as the company continues to meet its goals across a broad set of markets."
In addition to Spotfire, Hadfield has held senior executive roles in a number of technology companies; including Vice President of Sales and Marketing at Molecular Devices Inc.; Vice President of Marketing and Business Development at Oxford GlycoSciences and a number of management positions at Applied Biosystems.
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Bone Cancer Drug Targets Tumors, Spares Other OrgansNews
A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018